Treatment
Zanubrutinib clinical trials
We’re tracking 75 recruiting studies that include Zanubrutinib, each written for real people, not researchers, below.
Recruiting studies
- NCT05635162RecruitingPhase 2
Zanubrutinib plus rituximab for slow-growing mantle cell lymphoma
This trial studies whether combining zanubrutinib and rituximab can better control indolent (slow-growing) mantle cell lymphoma. It aims to improve how long participants can stay without the lymphoma worsening.
DerbyAges 18 years+ - NCT06959732RecruitingPhase 2
Zanubrutinib with G-CVP for untreated follicular lymphoma
This trial tests a combination of targeted therapy (zanubrutinib) and chemotherapy (G-CVP) for people with follicular lymphoma who have not had treatment before. It aims to see if this combination is safe and effective.
Beijing, Beijing MunicipalityAges 18–80 - NCT07126678Recruiting
Zanubrutinib, Bendamustine, and Obinutuzumab for advanced follicular lymphoma
This trial tests a 3-drug combination (Zanubrutinib, Bendamustine, and Obinutuzumab) for people with advanced follicular lymphoma who have not had treatment before. The goal is to see if a fixed-duration treatment plan can improve outcomes.
Nanjing, JiangsuAges 18–75 - NCT06859008RecruitingPhase 1
Zanubrutinib and sonrotoclax for B-cell lymphoma in diverse groups
This trial tests two targeted drugs, zanubrutinib and sonrotoclax, together for people with certain types of B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. It focuses on enrolling patients from racial and ethnic groups that are often underrepresented in research.
Duarte, CaliforniaAges 18 years+ - NCT06849713RecruitingPhase 2
New combination treatments for CLL or SLL
This trial tests two different combinations of targeted drugs for people with CLL or SLL who have not had prior treatment for their disease. The goal is to see if these combinations are safe and effective.
Boston, MassachusettsAges 18 years+ - NCT06854003RecruitingPhase 2
Study of new drug combo for untreated mantle cell lymphoma
This trial is testing a combination of chemotherapy and targeted drugs for people who have just been diagnosed with mantle cell lymphoma and haven't had any prior treatment (except short-term steroids or local radiation). It aims to see if adding newer targeted therapies can help keep the lymphoma in remission.
Phoenix, ArizonaAges 18 years+ - NCT06846463RecruitingPhase 2
Zanubrutinib for DLBCL with specific genetic changes
This trial tests a targeted drug called zanubrutinib combined with standard chemotherapy (R-CHOP) for people with DLBCL who have specific genetic changes in their tumor. The goal is to see if adding this drug can improve outcomes.
Richmond, VirginiaAges 18 years+ - NCT06839053RecruitingPhase 2
Study of sonrotoclax, rituximab, and zanubrutinib for CLL, SLL, and MCL
This trial tests a combination of three drugs (sonrotoclax, rituximab, and zanubrutinib) for people with chronic lymphocytic leukemia, small lymphocytic lymphoma, or mantle cell lymphoma. The goal is to see if the combination works better than current treatments.
Seattle, WashingtonAges 18 years+ - NCT06735664RecruitingPhase 1
Zanubrutinib and odronextamab for Richter's transformation
This trial tests a combination of two targeted drugs for people with Richter's transformation, an aggressive lymphoma that can develop from CLL. The goal is to see if this combination can help control the disease.
Duarte, CaliforniaAges 18 years+ - NCT06730542RecruitingPhase 1
Zanubrutinib plus pola-R-CHP and high-dose methotrexate for secondary CNS lymphoma
This trial tests a combination of targeted therapy (zanubrutinib) plus a standard chemo-immunotherapy regimen (pola-R-CHP) and high-dose methotrexate for people whose large B-cell lymphoma has spread to the brain or spinal cord. The goal is to see if this approach can effectively treat lymphoma in both the body and the central nervous system.
Miami, FloridaAges 18 years+ - NCT06375733RecruitingPhase 1/Phase 2
GFH009 plus zanubrutinib for relapsed large B-cell lymphoma
This trial tests a new targeted drug (GFH009) combined with another targeted drug (zanubrutinib) for people with diffuse large B-cell lymphoma that has returned or not improved after at least two prior treatments. It aims to see if this combination can shrink tumors and improve outcomes.
NanningAges 18 years+ - NCT06563505RecruitingPhase 2
Study of mosunetuzumab plus zanubrutinib for relapsed marginal zone lymphoma
This trial tests a combination of two drugs (mosunetuzumab and zanubrutinib) for people with marginal zone lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help control the lymphoma.
Houston, TexasAges 18 years+ - NCT06558604RecruitingPhase 2
Study of glofitamab with venetoclax for high-risk mantle cell lymphoma
This trial tests a new combination of drugs (glofitamab plus venetoclax, with or without zanubrutinib) for people with mantle cell lymphoma that is either newly diagnosed with high risk features, or has come back or not responded to earlier treatments. The goal is to see if these targeted therapies can improve outcomes.
BrugesAges 18–79 - NCT06561347RecruitingPhase 2
Zanubrutinib with bendamustine and rituximab for untreated Waldenstrom macroglobulinemia
This trial tests a combination of three drugs (zanubrutinib, bendamustine, and rituximab) for people with Waldenstrom macroglobulinemia who have not been treated before. The goal is to see if this combination is safe and effective.
Denver, ColoradoAges 18 years+ - NCT06544785RecruitingPhase 2
Zanubrutinib plus obinutuzumab for untreated CLL or SLL
This trial tests a combination of two targeted drugs, zanubrutinib (a pill) and obinutuzumab (an infusion), for people with untreated CLL or SLL who need treatment. The goal is to see if this combination works well and is safe.
AlicanteAges 18 years+ - NCT06468943Enrolling by invitationPhase 2
New drug combo for non-GCB diffuse large B-cell lymphoma
This trial tests a combination of three targeted drugs (polatuzumab vedotin, zanubrutinib, and R-CHP) for people newly diagnosed with a specific subtype of DLBCL called non-GCB. The goal is to see if this powerful mix can work better than standard treatment.
Suzhou, NanjingAges 18 years+ - NCT06471738RecruitingPhase 2
Targeted drug combo for untreated follicular lymphoma
This trial tests a combination of three targeted drugs (zanubrutinib, rituximab, and venetoclax) for people with untreated follicular lymphoma. The goal is to see if this combination works better than standard treatments and has manageable side effects.
BeijingAges 18 years+ - NCT06350318RecruitingPhase 2
Rituximab and Zanubrutinib for slow-growing B-cell lymphomas
This trial tests a combination of two targeted drugs (rituximab and zanubrutinib) for people with slow-growing B-cell lymphomas like marginal zone or follicular lymphoma. It may be a good option if you haven't had treatment for your lymphoma before and your disease needs therapy to manage symptoms.
Tampa, FloridaAges 18 years+ - NCT06029309RecruitingPhase 1/Phase 2
Zanubrutinib and tafasitamab for mantle cell lymphoma
This trial tests two targeted drugs, zanubrutinib and tafasitamab, for people with mantle cell lymphoma. The goal is to see if this combination works better than standard treatments.
Miami, FloridaAges 18 years+ - NCT06005870RecruitingPhase 2
Zanubrutinib with R-CHOP for newly diagnosed p53-positive DLBCL
This trial tests a new combination: zanubrutinib (a targeted pill) plus standard chemotherapy (R-CHOP) for people newly diagnosed with DLBCL whose cancer cells have high p53 protein levels. The goal is to see if adding this drug helps shrink tumors better than chemotherapy alone.
Wuhan, HubeiAges 18–75 - NCT05976763RecruitingPhase 3
Testing continuous vs. intermittent zanubrutinib for older adults with mantle cell lymphoma
This trial tests whether taking the targeted drug zanubrutinib continuously is better than taking it on a schedule with breaks for older adults with untreated mantle cell lymphoma. The goal is to find a treatment that works while reducing side effects.
Little Rock, ArkansasAges 60 years+ - NCT05873712RecruitingPhase 2
Zanubrutinib plus CAR-T for Richter syndrome
This Phase 2 trial tests whether a combination of zanubrutinib (an oral medicine) and CAR-T cell therapy can treat Richter syndrome, a type of lymphoma that develops in people with CLL/SLL. It may help shrink tumors and improve outcomes after the disease comes back or doesn’t respond to prior treatment.
New York, New YorkAges 18 years+ - NCT05168930RecruitingPhase 2
Zanubrutinib plus venetoclax for relapsed CLL or SLL
This Phase 2 study tests how well zanubrutinib (a targeted pill) combined with venetoclax (another targeted pill) works for adults with CLL/SLL that came back or progressed after prior treatment. It may help by stopping cancer cells through two different pathways, aiming to shrink disease and improve blood counts.
Scarborough, MaineAges 18 years+ - NCT05681195RecruitingPhase 2
Zanubrutinib plus pemetrexed for recurrent brain lymphomas
This trial tests zanubrutinib (a targeted lymphoma medicine) together with pemetrexed (chemotherapy) for lymphoma that has come back or did not respond well in or around the brain. It may help shrink measurable lymphoma and improve control of disease after prior treatments.
Miami, FloridaAges 18 years+
Common questions
- Are there clinical trials studying Zanubrutinib?
- Yes. Clin2 currently lists 75 recruiting studies that include Zanubrutinib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Zanubrutinib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Zanubrutinib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Zanubrutinib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.